ORYZON to give updates on corporate progress in September

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to 
develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in September.

Oryzon will participate at the H.C. Wainwright Global Investment Conference, which will be held on September 11-13 at the Lotte New York Palace Hotel in New York (USA) and virtually. The company will provide a corporate update and will also hold one-on-one meetings with pharmaceutical companies and global investors. Click on link for more info about the H.C. Wainwright Global Investment Conference

Oryzon has been invited to the Sachs Annual Biotech in Europe Forum in Basel (Switzerland) on September 20-21, where the company will participate in a panel entitled “Advanced Approaches to Neurodegenerative Diseases Panel”, which will be held on September 20. The company will also hold oneto-one meetings with pharmaceutical companies and global investors. Click on link for more info about the Sachs Annual Biotech in Europe Forum

Oryzon will attend the Third Annual Global Charcot Marie-Tooth (CMT) Research Convention in Cambridge, MA on September 22-23, where Oryzon’s Chief Medical Officer, Dr. Douglas V. Faller, will participate in a round table entitled “Pushing Boundaries in CMT Research: Early-Stage Biotech Companies' Evolution and Insights on Therapy Development” and our Oncology Project Leader Dr. Natalia Sacilotto will take part in a round table entitled “Patient-Powered Perspectives: Biotech Insights on CMT and Collaborating with Patients”. Additionally, the company will present during the poster session the data obtained in a CMT experimental model with its selective HDAC6 inhibitor ORY-4001. Click on link for more info about the Global CMT Research convention.

Executive directors of the company will attend BIO-Spain 2023, which will take place on September 26-28 in Barcelona, Spain. Besides regular one-on-one meetings, the company will moderate a KOL panel discussion focused on mental health and precision medicine and the potential of LSD1 inhibitors like vafidemstat. This panel, entitled “Mental Health and Personalized Medicine”, will take place on September 26 at 16:00-17:00 h CET, and will be chaired by Dr. Tamara Maes, Oryzon’s VicePresident, with the participation of Dr. Marc Ferrer, MD, PhD, Coordinator of the Comprehensive Care Program for Borderline Personality Disorder (BPD) for adolescents and young adults at the Vall d’Hebron University PRESS RELEASE 2023 Pioneering Personalized Medicine in Epigenetics Hospital (Spain), Dr. Clara Tang, Director of Research at the Kabuki Syndrome Foundation (UK) and Dr.  Siddharth Banka, MBBS, MRCPCH, PhD, Manchester Centre for Genomic Medicine (Manchester University NHS Trust). The company will also participate in a KOL panel discussion moderated by Mr. Jesús González Nieto-Márquez, Managing Director of BME, entitled “Want to be a “Rocket”? How stock markets boost the growth of biotech companies” with the participation of Mr. Roger Freixes, Partner of Cuatrecasas (Spain); Dr. Isabel Lozano, CEO of Atrys (Spain) and Dr. Carlos Buesa, CEO of Oryzon (Spain). This panel will take place on September 27 at 17:30-18:30 h CET. Click on link for more info about BIO-Spain.